Abstract
Vaccine development is a vital process focused on preventing infectious diseases and enhancing public health. It entails comprehensive research and collaboration among scientists, healthcare professionals, and regulatory agencies. The process generally comprises multiple phases: exploratory research, preclinical testing, clinical trials, and regulatory approval. Recent technological advancements, such as mRNA and viral vector platforms, have accelerated and improved the efficiency of vaccine development. Vaccines protect individuals and help establish herd immunity, thereby decreasing disease transmission. The continuous advancement of vaccine science is crucial for tackling existing and emerging global health challenges.Research significance: The importance of vaccine development is highlighted by its essential role in managing infectious diseases, improving public health, and preventing outbreaks. Vaccines have achieved the eradication or significant reduction of illnesses such as smallpox and polio, showcasing their effectiveness in protecting communities. They not only provide individual protection but also enhance herd immunity, reducing disease transmission to at-risk populations. Additionally, vaccine development drives innovation within medical science, resulting in technological and methodological advancements. In the context of emerging pathogens, a strong vaccine development framework is vital for global health security, ensuring readiness and resilience against future health challenges.Methodology: The vaccine development methodology follows a structured and multi-phase approach. Initially, researchers conduct exploratory research to identify potential antigens. This step is succeeded by preclinical testing, where candidate vaccines undergo evaluation in laboratory settings and animal studies to determine their safety and ability to provoke an immune response. Candidates that prove successful move on to clinical trials, which are divided into three phases: Phase 1 assesses safety and dosage in a small group of participants, Phase 2 broadens the participant base to further evaluate safety and effectiveness, and Phase 3 entails extensive testing to validate efficacy and monitor any adverse effects. After successful trials, regulatory approval is pursued, followed by post-marketing surveillance to ensure continued safety.Alternative: mRNA Vaccines, Viral Vector Vaccines, Protein Subunit Vaccines, DNA Vaccines, Virus-Like Particle (VLP) Vaccines, Live Attenuated Vaccines, Inactivated or Killed Vaccines, Nano particle Vaccines, Whole-Cell Vaccines, Therapeutic VaccinesEvaluation preference: Efficacy, Safety, Immunogenicity, Stability, Cost-Effectiveness, Accessibility and DeliveryResults: mRNA vaccines are at the top of the rankings, while therapeutic vaccines are at the bottom.